Statins for preventing preeclampsia

Themistoklis Paraskevas; Georgios Gakis; Michail Papapanou; Theodoros N Sergentanis; Alexandros Sotiriadis; Charalampos S Siristatidis

doi:10.1002/14651858.CD016133

Statins for preventing preeclampsia

Cochrane Database Syst Rev. 2025 Mar 18;3(3):CD016133. doi: 10.1002/14651858.CD016133.

Authors

Themistoklis Paraskevas¹, Georgios Gakis², Michail Papapanou³, Theodoros N Sergentanis⁴, Alexandros Sotiriadis⁵, Charalampos S Siristatidis⁶

Affiliations

¹ Department of Nephrology, General University Hospital of Patras, Patras, Greece.
² General University Hospital of Patras, University of Patras, Patras, Greece.
³ Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece.
⁵ Second Department of Obstetrics and Gynaecology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁶ Assisted Reproduction Unit, Second Department of Obstetrics and Gynaecology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the relative benefits and harms of statins for preeclampsia prevention in pregnant women.

MeSH terms

Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Pre-Eclampsia* / prevention & control
Pregnancy
Randomized Controlled Trials as Topic

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors